OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
April 27, 2023Final results from Phase 2 study of pegsitacianine for image-guided cancer surgery featured in oral presentation
SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, taking place June 2-6, 2023 at McCormick Place, Chicago, Illinois.
Presentation Overview:
|
TITLE: |
Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study |
|
|
PRESENTER: |
Patrick Wagner, MD, Director of Complex General Surgical Oncology, Allegheny Health Network Cancer Institute |
|
|
DATE: |
June 5, 2023 |
|
|
SESSION TIME: |
8:00 – 11:00 am CT |
|
|
SESSION: |
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology |
|
|
ABSTRACT: |
3003 |
About OncoNano Medicine
OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image guided surgery and a platform of immuno-oncology therapeutics that activate and guide the body’s immune system to target cancer.
OncoNano’s lead development candidate is pegsitacianine, a novel fluorescent nanoprobe using the ON-BOARD platform, that is being studied as a real-time surgical imaging agent for use in multiple cancer surgeries and is advancing towards a pivotal clinical trial to aid in tumor detection of peritoneal carcinomatosis. ONM-501, OncoNano’s second development program, is a next generation STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the first half of 2023. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at www.OncoNano.com.
Contacts
MacDougall Advisors
Lauren Arnold
781-235-3060
[email protected]